Iron Deficiency Assessment and Repletion in Adolescents with Restless Legs Syndrome

Diagnostic Laboratory Indicators

• Mean corpuscular hemoglobin (MCH) ≈ 24 pg confirms hypochromia, supporting a diagnosis of iron‑deficiency anemia in adolescents. 1

Iron Status Thresholds for RLS Treatment

• Ferritin ≤ 100 ng/mL or transferrin saturation < 20 % should trigger iron repletion to treat both anemia and restless‑legs symptoms, reflecting the higher brain‑iron requirements for RLS. (American Academy of Sleep Medicine, 2025; strong recommendation) 2

Intravenous Iron Therapy

• Intravenous ferric carboxymaltose 1000 mg is strongly recommended as first‑line iron repletion for adolescents with RLS and low iron stores, providing rapid, complete restoration without gastrointestinal side effects. (American Academy of Sleep Medicine, 2025; strong recommendation) 2
• Alternative IV formulations (ferumoxytol or low‑molecular‑weight iron dextran) are conditionally recommended when ferric carboxymaltose is unavailable. (American Academy of Sleep Medicine, 2025; conditional recommendation) 2

Oral Iron Therapy

• Ferrous sulfate 325–650 mg daily (or every other day) is conditionally recommended when intravenous access is problematic. (American Academy of Sleep Medicine, 2025; conditional recommendation) 3
• Oral iron is effective but slower to correct deficiency and is commonly associated with constipation, the leading cause of discontinuation in adolescents; monitoring for this side effect is advised. (American Academy of Sleep Medicine, 2025; conditional recommendation) 4

Adjunctive RLS Management

• Discontinue medications that exacerbate RLS (e.g., serotonergic antidepressants, dopamine antagonists, centrally acting antihistamines). (American Academy of Sleep Medicine, 2025) 2
• Lifestyle modifications—avoid caffeine and alcohol, maintain good sleep hygiene, and screen for obstructive sleep apnea when indicated—are recommended to reduce RLS severity. (American Academy of Sleep Medicine, 2025) 2
• If symptoms persist after adequate iron repletion, gabapentinoids (gabapentin, gabapentin enacarbil, pregabalin) receive a strong recommendation as first‑line pharmacologic therapy for RLS. (American Academy of Sleep Medicine, 2025; strong recommendation) 2

Expected Timeline of Clinical Improvement

• Intravenous iron can produce noticeable improvement in anemia parameters and RLS symptoms within weeks, whereas oral iron typically yields gradual improvement over 4–12 weeks. (American Academy of Sleep Medicine, 2025) 2

Evidence‑Based Management of Restless Legs Syndrome (RLS)

Guideline Position on Topical Therapies

• The 2025 American Academy of Sleep Medicine (AASM) guidelines do not recommend any topical therapy (including magnesium or capsaicin creams) for the treatment of RLS. 5, 6, 7

First‑Line Pharmacologic Therapies (Gabapentinoids)

• Gabapentin enacarbil is given a strong recommendation as a first‑line agent for RLS. 5
• Gabapentin (standard formulation) receives a strong recommendation as a first‑line agent for RLS. 5
• Pregabalin is also assigned a strong recommendation for first‑line treatment of RLS. 5

Iron Repletion Strategy

• Intravenous ferric carboxymaltose 1000 mg is strongly recommended for patients with RLS who have low iron stores (ferritin ≤ 100 ng/mL or transferrin saturation < 20%). 5, 8
• Oral ferrous sulfate 325–650 mg daily (or every other day) is conditionally recommended for the same iron‑deficient RLS population. 5

Medication Safety and Pitfalls

• Dopamine agonists (e.g., pramipexole, ropinirole, rotigotine) should not be used as first‑line therapy because they carry a 7–10 % annual risk of augmentation (worsening of symptoms). 6
• Topical preparations (magnesium or capsaicin) are discouraged because systemic absorption and central nervous system effects are required for effective RLS treatment. 5
• Valerian is advised against by the AASM (conditional recommendation) due to insufficient benefit and potential adverse effects. 7, 9

Clinical Assessment and Treatment Algorithm

• Assess iron status in all patients with RLS by measuring serum ferritin and transferrin saturation. 7
• If ferritin ≤ 100 ng/mL or TSAT < 20 %, initiate iron supplementation—preferably intravenous ferric carboxymaltose, with oral ferrous sulfate as an alternative. 7
• Review current medications and discontinue any agents known to exacerbate RLS (e.g., serotonergic antidepressants, dopamine antagonists, antihistamines). 8
• When pharmacologic therapy is indicated, start a gabapentinoid (gabapentin enacarbil, gabapentin, or pregabalin). 8
• If response is inadequate, consider second‑line options such as low‑dose opioids (e.g., methadone 5–10 mg daily). 5

Management of Severe Refractory Restless Legs Syndrome (RLS)

Immediate Assessment & Iron Repletion

• Serum ferritin and transferrin saturation should be measured promptly in every patient with RLS because iron deficiency can worsen symptoms and is reversible – recommended by the American Academy of Sleep Medicine (AASM) 2025 guidelines (strong recommendation) 10.

First‑Line Pharmacologic Therapy

• Gabapentinoids are endorsed as first‑line agents for RLS; the 2025 AASM guidelines assign a strong recommendation to each of the three agents (gabapentin enacarbil, gabapentin immediate‑release, and pregabalin) for improving symptoms in this condition 10.
• Gabapentin enacarbil – strong recommendation as a first‑line option for RLS (AASM 2025) 10.
• Gabapentin (standard formulation) – strong recommendation as a first‑line option for RLS (AASM 2025) 10.
• Pregabalin – strong recommendation as a first‑line option for RLS (AASM 2025) 10.
• Initiation of gabapentinoid therapy should occur without waiting for iron repletion; simultaneous start is advised to achieve faster symptom control (AASM 2025) 10.

Dopamine Agonist Use – Critical Pitfall

• Dopamine agonists (e.g., pramipexole, ropinirole, rotigotine) are not recommended as first‑line therapy for RLS because they carry a 7–10 % annual risk of augmentation, an iatrogenic worsening of the disorder (AASM 2025) 10.
• The 2025 AASM guidelines explicitly advise against routine use of these dopamine agonists due to the long‑term risk of augmentation (strong recommendation against) 10.

Escalation for Refractory Disease

• If symptoms remain refractory after appropriate iron repletion and gabapentinoid therapy, low‑dose opioid therapy (e.g., methadone 5–10 mg daily) should be added as the next therapeutic step (AASM 2025) 10.